🟢 Pharming Group is trading 10% up after preliminary Q3 revenue exceeded expectations

Pharming Group is trading at €0.94, up 10.02% after preliminary Q3 revenue exceeded market expectations.

• On October 22, Pharming Group announced preliminary Q3 revenue of US$117.6 million, up about 21% year over year, with strong RUCONEST and Joenja performance.
• It narrowed 2026 revenue guidance to US$380 million–US$390 million from US$375 million–US$395 million and lowered operating expense guidance.
• Full Q3 results are scheduled for October 27.